<DOC>
	<DOCNO>NCT01851603</DOCNO>
	<brief_summary>This brief inpatient study determine safety new drug healthy people .</brief_summary>
	<brief_title>Phase I Study Evaluate Safety Pharmacokinetics Oral Doses Anvylic-3288 Healthy Subjects</brief_title>
	<detailed_description>AVL-3288 , `` first class '' small molecule , selective allosteric modulator α7 nAChR , implicate cognitive deficit patient neurologic psychiatric disorder , include schizophrenia , Alzheimer 's disease attention deficit hyperactivity disorder . The mechanism action , allosteric modulation α7 nAChR improvement cognitive memory function relevant animal model patient clearly describe recent literature . The effect AVL-3288 strongly support rationale use schizophrenia give dose effect relationship , peak low dose rat ( HED 3 mg ) , rodent schizophrenia memory model . Phase I , single-center , inpatient , randomize , double-blind , placebo-controlled , dose escalate study evaluate safety , tolerability pharmacokinetic profile single oral dos AVL-3288 healthy subject . Subjects hospitalize University Colorado Clinical Research Center ( CTSA ) 12 hour period single dose . Then ambulatory 24 48 hour observation washout period 10 . Patients receive evoke potential measurement , P50 sensory gate paradigm , Repeatable Battery Assessment Neuropsychological Status .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Healthy volunteer Substance use . We accept inquiry email .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Schizophrenia</keyword>
</DOC>